What are your top takeaways from ADA 2026?

Lots of drugs in pipeline.

Amylin receptor agonists may provide better tolerability and reasonable efficacy and become the first-line nutrient-stimulated hormone (NuSH) therapy with time.

Do not follow titration in the prescribing information (PI) of glucagon-like peptide-1 receptor agonist (GLP-1 RA)...